AMOEBA (EPA:ALMIB) - AMOEBA publishes a first scientific article concerning its biocontrol application to fight grapevine downy mildew

Transparency directive : regulatory news

11/08/2020 17:45

PRESS RELEASE

     Amoéba publishes a first scientific article concerning its biocontrol
                  application to fight grapevine downy mildew

Chassieu (France), August 11 2020 - AMOÉBA (FR0011051598 - AMEBA), producer of
a biological biocide capable of eliminating the risk in water and human wounds,
and of a biocontrol product for plant protection, still in the testing phase,
announces the publication of a first scientific article on its biocontrol
application (https://www.mdpi.com/2223-7747/9/8/1013/pdf) in the special issue
" Natural Products for Plant Pest and Disease Control " of Plants, journal of
the MDPI Group, peer-reviewed.

This paper presents, for the first time to the international scientific
community, a major innovation in the field of biocontrol involving a natural
product based on an amoeba, Willaertia magna C2c Maky. Scientific data
demonstrating the dual mode of action of the lysate to control grapevine downy
mildew are presented :
- the indirect effect via the stimulation of the plant's natural defences
- and the direct anti-germinative effect against the pathogen, Plasmopara
  viticola, responsible for grapevine downy mildew.

The data, collected in trials carried out by independent service providers,
that have demonstrated efficiency in greenhouses and in the field (2019 season)
are also published. They show that lysate of the amoeba Willaertia magna C2c
Maky, a product of natural origin, can reduce the disease on bunches in the
field by 77% without any harmful effects on humans or the environment. Indeed,
a summary of toxicity and ecotoxicity data, generated under Good Laboratory
Practices by accredited independent laboratories are also available on the
website of the journal (http://www.mdpi.com/2223- 7747/9/8/1013/s1).

" This first article, dealing with the efficacy of our biocontrol solution
against grapevine downy mildew, is part of an ongoing effort to increase
scientific knowledge on the amoeba Willaertia magna C2c Maky. It confirms its
strong potential, this time as a plant protection agent. We are continuing R&D
operations and tests on other crops, the results of which will also be the
subject of new publications," says Dr Sandrine DEMANECHE, scientific manager of
Amoéba.

As a reminder, the marketing of biocontrol products containing this active
substance is envisaged by Amoéba in 2024 in Europe (dossier submitted, cf.
Press Release of 29 May 2020) and in the first half of 2022 in the United
States (submission envisaged in July 2020, cf. Press Release of 29 April 2020,
postponed to September 2020). The prioritization of Amoéba's Regulatory
Affairs Department resources on biocontrol application leads to a delay in the
filing of a new application for biocidal application in the United States,
which was envisaged in mid 2020 (see Universal Registration Document of April
30, 2020) and will be submitted at the end of 2020, with first marketing in the
United States estimated in the first half of 2022.

About AMOEBA:
Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.
Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on the compartment C of Euronext
Paris. The Company is a member of the BPIfrance Excellence network and is
eligible for the PEA-PME SME equity savings plan setup. More information on
www.amoeba-biocide.com.
(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba
Valérie FILIATRE
General Manager
+33 4 26 69 16 00
valerie.filiatre@amoeba-biocide.com

Investors and Media Relations
Grégory BOSSON / Mathieu CALLEUX
Agence Calyptus
+33(0)1 53 65 37 90
amoeba@calyptus.net

Disclaimer
This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the Universal
Registration Document of AMOEBA filed with the French Financial Markets
Authority (Autorité des Marchés Financiers) on April 30, 2020 under number
D20-0416 (a copy of which is available on www.amoeba-biocide.com). The
forward-looking statements contained in this press release are also subject to
risks not yet known to AMOEBA or not currently considered material by AMOEBA.
The occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of AMOEBA to be materially
different from such forward-looking statements.

AMOEBA's latest news

02/05/2024 18:00

AMOEBA (EPA:ALMIB) - AMOEBA publishes a first scientific article concerning its biocontrol application to fight grapevine downy mildew

Transparency directive : regulatory news

AMOEBA's latest news

Other stories